Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer therapeutics

Pulling the plug on BCL-XL

Nature Chemical Biology volume 9, pages 351–352 (2013)Cite this article

Subjects

BCL-XL and other anti-apoptotic BCL-2 family proteins serve as guardians of cellular survival. A new selective small-molecule inhibitor of BCL-XL is developed to promote apoptosis in cancers that are addicted to BCL-XL.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Targeting BCL-2 family proteins for cancer therapy.

References

  1. Youle, R.J. & Strasser, A. Nat. Rev. Mol. Cell Biol. 9, 47–59 (2008).

    Article  CAS  Google Scholar 

  2. Davids, M.S. & Letai, A. J. Clin. Oncol. 30, 3127–3135 (2012).

    Article  CAS  Google Scholar 

  3. Walensky, L.D. J. Clin. Oncol. 30, 554–557 (2012).

    Article  CAS  Google Scholar 

  4. Lessene, G. Nat. Chem. Biol. 9, 390–397 (2013).

    Article  CAS  Google Scholar 

  5. Czabotar, P.E. et al. Cell 152, 519–531 (2013).

    Article  CAS  Google Scholar 

  6. Kim, H. et al. Mol. Cell 36, 487–499 (2009).

    Article  CAS  Google Scholar 

  7. Ren, D. et al. Science 330, 1390–1393 (2010).

    Article  CAS  Google Scholar 

  8. Souers, A.J. et al. Nat. Med. 19, 202–208 (2013).

    Article  CAS  Google Scholar 

  9. Beroukhim, R. et al. Nature 463, 899–905 (2010).

    Article  CAS  Google Scholar 

  10. Bean, G.R. et al. Sci. Signal. 6, ra20 (2013).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Paul S. Jeng and Emily H. Cheng are at the Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.,

    Paul S Jeng & Emily H Cheng

  2. Paul S. Jeng is also in the Program in Pharmacology, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, New York, USA.,

    Paul S Jeng

  3. Emily H. Cheng is also at the Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.,

    Emily H Cheng

  4. Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Cornell University, New York, New York, USA

    Emily H Cheng

Authors
  1. Paul S Jeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emily H Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emily H Cheng.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jeng, P., Cheng, E. Pulling the plug on BCL-XL. Nat Chem Biol 9, 351–352 (2013). https://doi.org/10.1038/nchembio.1256

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nchembio.1256

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer